Gene therapy trial aims to halt rare eye disease
NCT ID NCT05694598
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 20 times
Summary
This early-stage study tests a new gene therapy called VGR-R01 in 12 adults with Bietti Crystalline Dystrophy, a rare inherited eye disease that causes vision loss. The main goal is to check if the treatment is safe and tolerable. Researchers will monitor for side effects and changes in vision over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIETTI CRYSTALLINE DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Vitalgen Biopharma Co.,Ltd.
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.